scispace - formally typeset
Search or ask a question
Author

Lies Laenen

Bio: Lies Laenen is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Medicine & Hantavirus. The author has an hindex of 13, co-authored 28 publications receiving 727 citations. Previous affiliations of Lies Laenen include Rega Institute for Medical Research.

Papers
More filters
Journal ArticleDOI
Abulikemu Abudurexiti1, Scott Adkins2, Daniela Alioto3, S. V. Alkhovsky, Tatjana Avšič-Županc4, Matthew J. Ballinger5, Dennis A. Bente6, Martin Beer7, Eric Bergeron1, Carol D. Blair8, Thomas Briese9, Michael J. Buchmeier10, Felicity J. Burt11, Charles H. Calisher8, Chénchén Cháng12, Rémi N. Charrel13, Il-Ryong Choi14, J. Christopher S. Clegg, Juan Carlos de la Torre15, Xavier de Lamballerie13, Fēi Dèng, Francesco Di Serio, Michele Digiaro, Michael A. Drebot16, Xiǎoméi Duàn12, Hideki Ebihara17, Toufic Elbeaino, Koray Ergünay18, Charles F. Fulhorst6, Aura R. Garrison19, George Fú Gāo20, Jean-Paul Gonzalez21, Martin H. Groschup7, Stephan Günther22, Anne Lise Haenni23, Roy A. Hall24, Jussi Hepojoki25, Jussi Hepojoki26, Roger Hewson27, Zhìhóng Hú, Holly R. Hughes1, Miranda Gilda Jonson28, Sandra Junglen29, Boris Klempa30, Jonas Klingström31, Chūn Kòu12, Lies Laenen32, Amy J. Lambert1, Stanley A. Langevin33, Dan Liu34, Igor S. Lukashevich35, Tāo Luò1, Chuánwèi Lǚ, Piet Maes32, William Marciel de Souza36, Marco Marklewitz29, Giovanni P. Martelli37, Keita Matsuno38, Nicole Mielke-Ehret39, Maria Minutolo3, Ali Mirazimi40, Abulimiti Moming12, Hans Peter Mühlbach39, Rayapati A. Naidu41, Beatriz Navarro, Márcio Roberto Teixeira Nunes, Gustavo Palacios19, Anna Papa42, Alex Pauvolid-Corrêa43, Janusz T. Paweska, Jié Qiáo, Sheli R. Radoshitzky19, R. O. Resende44, Víctor Romanowski45, Amadou A. Sall46, Maria S. Salvato47, Takahide Sasaya48, Shū Shěn, Xiǎohóng Shí49, Yukio Shirako50, Peter Simmonds51, Manuela Sironi, Jin Won Song52, Jessica R. Spengler1, Mark D. Stenglein8, Zhèngyuán Sū, Sùróng Sūn12, Shuāng Táng, Massimo Turina53, Bó Wáng, Chéng Wáng1, Huálín Wáng, Jūn Wáng, Taiyun Wei54, Anna E. Whitfield55, F. Murilo Zerbini56, Jìngyuàn Zhāng12, Lěi Zhāng, Yànfāng Zhāng, Yong-Zhen Zhang20, Yong-Zhen Zhang57, Yújiāng Zhāng1, Xueping Zhou, Lìyǐng Zhū, Jens H. Kuhn58 
Centers for Disease Control and Prevention1, United States Department of Agriculture2, University of Naples Federico II3, University of Ljubljana4, Mississippi State University5, University of Texas Medical Branch6, Friedrich Loeffler Institute7, Colorado State University8, Columbia University9, University of California, Irvine10, University of the Free State11, Xinjiang University12, Aix-Marseille University13, International Rice Research Institute14, Scripps Research Institute15, Public Health Agency of Canada16, Mayo Clinic17, Hacettepe University18, United States Army Medical Research Institute of Infectious Diseases19, Chinese Center for Disease Control and Prevention20, Kansas State University21, Bernhard Nocht Institute for Tropical Medicine22, Paris Diderot University23, University of Queensland24, University of Helsinki25, University of Zurich26, Public Health England27, Seoul National University28, Charité29, Slovak Academy of Sciences30, Karolinska Institutet31, Katholieke Universiteit Leuven32, University of Washington33, Wuhan University of Science and Technology34, University of Louisville35, University of São Paulo36, University of Bari37, Hokkaido University38, University of Hamburg39, Public Health Agency of Sweden40, Washington State University41, Aristotle University of Thessaloniki42, Oswaldo Cruz Foundation43, University of Brasília44, National University of La Plata45, Pasteur Institute46, University of Maryland, Baltimore47, National Agriculture and Food Research Organization48, University of Glasgow49, University of Tokyo50, University of Oxford51, Korea University52, National Research Council53, Fujian Agriculture and Forestry University54, North Carolina State University55, Universidade Federal de Viçosa56, Fudan University57, National Institutes of Health58
TL;DR: The updated taxonomy of the order Bunyavirales now accepted by the International Committee on Taxonomy of Viruses (ICTV) is presented.
Abstract: In February 2019, following the annual taxon ratification vote, the order Bunyavirales was amended by creation of two new families, four new subfamilies, 11 new genera and 77 new species, merging of two species, and deletion of one species. This article presents the updated taxonomy of the order Bunyavirales now accepted by the International Committee on Taxonomy of Viruses (ICTV).

237 citations

Journal ArticleDOI
TL;DR: Cette position est basée sur une recension sommaire de la documentation scientifique (PubMed, littérature grise) identifiée par des professionnels en évaluation et pharmaciens de l'INESSS.
Abstract: CONTEXTE: Le présent document ainsi que les constats et prises de position qu'il énonce ont été rédigés en réponse à une interpellation du ministère de la Santé et des Services sociaux dans le contexte de l'urgence sanitaire liée à la maladie à coronavirus (COVID-19) au Québec Cette position est basée sur une recension sommaire de la documentation scientifique (PubMed, littérature grise) identifiée par des professionnels en évaluation et pharmaciens de l'INESSS Par ailleurs, son contenu ne repose pas sur une recherche exhaustive de la littérature et une évaluation de la qualité des études avec des outils standardisés Dans les circonstances d'une telle urgence de santé publique, l'INESSS reste à l'affût de toutes nouvelles données susceptibles de faire évoluer sa position Ainsi, des mises à jour sont prévues POSITION DE L'INESSS: Étant donné l'absence de données cliniques documentant l'effet de la colchicine sur la cascade inflammatoire accompagnant certaines formes graves de syndrome respiratoire aigu sévère causées par des coronavirus: -Il n'est pas recommandé d'administrer de la colchicine pour le traitement des patients ayant un diagnostic confirmé ou suspecté de la COVID-19 en milieu communautaire -Il est jugé prématuré, en dehors d'un protocole de recherche, d'administrer de la colchicine à des patients ayant un diagnostic confirmé ou suspecté de la COVID-19 OBJET DE LA DEMANDE: L'administration de la colchicine à toute personne atteinte de la COVID-19 en communauté est-elle une option envisageable? COLCHICINE: La colchicine est un alcaloïde extrait de la plante de l'espèce Colchicum (Colchicum autumnale) Ce médicament antiinflammatoire est indiqué pour la prophylaxie et le traitement des crises de goutte ainsi que pour le traitement de la fièvre méditerranéenne familiale Il est également utilisé pour le traitement de la péricardite virale Bien que son mode d'action exact dans le traitement de la goutte ne soit pas complètement élucidé, l'effet anti-inflammatoire de la colchicine est relativement sélectif pour l'arthrite goutteuse aiguë à dépôt de cristaux d'urate CONSTATS DE L'INESSS: Le mécanisme d'action de la colchicine (qui cible l'inflammasome) est très différent de celui des anti-inflammatoires non-stéroïdiens (AINS) Ces derniers inhibent la cyclooxygénase et pourraient résulter en la production de leucotriènes pro-inflammatoires, ce qui ne survient pas avec la colchicine Les inflammasomes sont des oligomères multiprotéiques cytosoliques du système immunitaire inné responsables de l'activation de la réponse inflammatoire [Martinez et al , 2018] La colchicine inhibe l'inflammasome NLRP3 et la caspase-1 (qui clive le précurseur de l'IL-1) ainsi que la réponse L'IL-1bêta est un puissant médiateur inflammatoire Cette interleukine est synthétisée sous la forme de précurseur, la pro-ILbêta, avec peu ou pas d'activité biologique Pour être sécrétée et être active, elle doit subir un traitement protéolytique médiée par la caspase 1 Ce mécanisme de régulation est important puisqu'il maintient l'IL-1 dans un état inactif, minimisant ainsi le risque d'une flambée inflammatoire [Afonina et al , 2015] Une étude récente a montré que la colchicine à faible dose (0,5 mg/jour) réduisait de façon significative le risque d'évènements cardiovasculaires ischémiques initiaux et totaux en comparaison à un placébo chez des patients avec crise cardiaque récente [Klingenberg et Nitschmann, 2020;Tardif et al , 2019] Aucune étude clinique ne permet de relier l'effet anti-inflammatoire de la colchicine à un effet sur la progression d'une infection avec un coronavirus Une étude (COLCORONA) est en voie de réalisation au Québec (Institut de cardiologie de Montréal) ayant pour but de déterminer si le traitement à court terme des patient COVID-19 positifs en communauté avec la colchicine réduit le taux de décès et de complications pulmonaires liées à la COVID-19 Le profil d'innocuité de la colchicine est marqué par des troubles gastro-intestinaux doses-dépendants (diarrhées, nausées, vomissements), des réactions d'hypersensibilité (urticaire, prurit), une élévation des enzymes hépatiques, notamment;des réactions extra-pyramidales sont également possibles L'administration chez des patients présentant une insuffisance rénale ou hépatique avec un inhibiteur puissant du cytochrome 3A4 (ex inhibiteurs de protéase comme le ritonavir, macrolides comme l'azithromycine) ou un inhibiteur de la glycoprotéine P constitue une contre-indication Aucun des guides consultés (Belgique [Van Ierssel et al , 2020], Chine [China NHC, 2020], France [HCSP, 2020], Italie [SIMIT, 2020], Université de Washington [UW Medicine, 2020], Université du Michigan [Michigan Medicine, 2020]) n'a inclus la colchicine parmi les choix de traitement pour la COVID-19

210 citations

Journal ArticleDOI
Jens H. Kuhn1, Scott Adkins2, Daniela Alioto3, S. V. Alkhovsky4  +231 moreInstitutions (125)
TL;DR: The updated taxonomy of Negarnaviricota is presented, as now accepted by the ICTV, after the phylum was amended and emended in March 2020.
Abstract: In March 2020, following the annual International Committee on Taxonomy of Viruses (ICTV) ratification vote on newly proposed taxa, the phylum Negarnaviricota was amended and emended. At the genus rank, 20 new genera were added, two were deleted, one was moved, and three were renamed. At the species rank, 160 species were added, four were deleted, ten were moved and renamed, and 30 species were renamed. This article presents the updated taxonomy of Negarnaviricota as now accepted by the ICTV.

168 citations

Journal ArticleDOI
27 Aug 2019-Viruses
TL;DR: This work summarizes affirmed taxonomic modifications of this family from 2016 to 2019 and outlines an objective framework that can be used in future classification schemes when more hantavirids sequences will be available.
Abstract: In recent years, negative-sense RNA virus classification and taxon nomenclature have undergone considerable transformation. In 2016, the new order Bunyavirales was established, elevating the previous genus Hantavirus to family rank, thereby creating Hantaviridae. Here we summarize affirmed taxonomic modifications of this family from 2016 to 2019. Changes involve the admission of >30 new hantavirid species and the establishment of subfamilies and novel genera based on DivErsity pArtitioning by hieRarchical Clustering (DEmARC) analysis of genomic sequencing data. We outline an objective framework that can be used in future classification schemes when more hantavirids sequences will be available. Finally, we summarize current taxonomic proposals and problems in hantavirid taxonomy that will have to be addressed shortly.

83 citations


Cited by
More filters
01 Jun 2012
TL;DR: SPAdes as mentioned in this paper is a new assembler for both single-cell and standard (multicell) assembly, and demonstrate that it improves on the recently released E+V-SC assembler and on popular assemblers Velvet and SoapDeNovo (for multicell data).
Abstract: The lion's share of bacteria in various environments cannot be cloned in the laboratory and thus cannot be sequenced using existing technologies. A major goal of single-cell genomics is to complement gene-centric metagenomic data with whole-genome assemblies of uncultivated organisms. Assembly of single-cell data is challenging because of highly non-uniform read coverage as well as elevated levels of sequencing errors and chimeric reads. We describe SPAdes, a new assembler for both single-cell and standard (multicell) assembly, and demonstrate that it improves on the recently released E+V-SC assembler (specialized for single-cell data) and on popular assemblers Velvet and SoapDeNovo (for multicell data). SPAdes generates single-cell assemblies, providing information about genomes of uncultivatable bacteria that vastly exceeds what may be obtained via traditional metagenomics studies. SPAdes is available online ( http://bioinf.spbau.ru/spades ). It is distributed as open source software.

10,124 citations

Journal ArticleDOI
28 Oct 2020-eLife
TL;DR: It is shown that functional SARS-CoV-2 S protein variants with mutations in the receptor-binding domain (RBD) and N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be readily selected.
Abstract: Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2. Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents. However, the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear. Using a recombinant chimeric VSV/SARS-CoV-2 reporter virus, we show that functional SARS-CoV-2 S protein variants with mutations in the receptor-binding domain (RBD) and N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be readily selected. Notably, SARS-CoV-2 S variants that resist commonly elicited neutralizing antibodies are now present at low frequencies in circulating SARS-CoV-2 populations. Finally, the emergence of antibody-resistant SARS-CoV-2 variants that might limit the therapeutic usefulness of monoclonal antibodies can be mitigated by the use of antibody combinations that target distinct neutralizing epitopes.

1,164 citations

Journal ArticleDOI
TL;DR: The relationship between the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remains unclear as discussed by the authors.
Abstract: Background The relationship between the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remains unclear. Metho...

714 citations

Journal ArticleDOI
TL;DR: The findings suggest that the patient was infected by SARS-CoV-2 on two separate occasions by a genetically distinct virus, suggesting that previous exposure to Sars-Cov-2 might not guarantee total immunity in all cases.
Abstract: Summary Background The degree of protective immunity conferred by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently unknown. As such, the possibility of reinfection with SARS-CoV-2 is not well understood. We describe an investigation of two instances of SARS-CoV-2 infection in the same individual. Methods A 25-year-old man who was a resident of Washoe County in the US state of Nevada presented to health authorities on two occasions with symptoms of viral infection, once at a community testing event in April, 2020, and a second time to primary care then hospital at the end of May and beginning of June, 2020. Nasopharyngeal swabs were obtained from the patient at each presentation and twice during follow-up. Nucleic acid amplification testing was done to confirm SARS-CoV-2 infection. We did next-generation sequencing of SARS-CoV-2 extracted from nasopharyngeal swabs. Sequence data were assessed by two different bioinformatic methodologies. A short tandem repeat marker was used for fragment analysis to confirm that samples from both infections came from the same individual. Findings The patient had two positive tests for SARS-CoV-2, the first on April 18, 2020, and the second on June 5, 2020, separated by two negative tests done during follow-up in May, 2020. Genomic analysis of SARS-CoV-2 showed genetically significant differences between each variant associated with each instance of infection. The second infection was symptomatically more severe than the first. Interpretation Genetic discordance of the two SARS-CoV-2 specimens was greater than could be accounted for by short-term in vivo evolution. These findings suggest that the patient was infected by SARS-CoV-2 on two separate occasions by a genetically distinct virus. Thus, previous exposure to SARS-CoV-2 might not guarantee total immunity in all cases. All individuals, whether previously diagnosed with COVID-19 or not, should take identical precautions to avoid infection with SARS-CoV-2. The implications of reinfections could be relevant for vaccine development and application. Funding Nevada IDEA Network of Biomedical Research, and the National Institute of General Medical Sciences (National Institutes of Health).

638 citations

Journal ArticleDOI
V J Hall1, Sarah Foulkes2, Andre Charlett1, Ana Atti2  +302 moreInstitutions (3)
TL;DR: The SARS-CoV-2 Immunity and Reinfection Evaluation study as mentioned in this paper showed that a previous history of SARS infection was associated with an 84% lower risk of infection, with median protective effect observed 7 months following primary infection.

492 citations